Mizuho cut shares of Horizon Pharma PLC (NASDAQ:HZNP) from a buy rating to a neutral rating in a report issued on Tuesday, May 9th. Mizuho currently has $10.00 target price on the biopharmaceutical company’s stock, down from their previous target price of $22.00.
A number of other equities research analysts have also commented on HZNP. Zacks Investment Research lowered Horizon Pharma PLC from a hold rating to a sell rating in a research report on Wednesday, February 1st. Guggenheim started coverage on Horizon Pharma PLC in a research report on Monday, February 27th. They issued a buy rating and a $30.00 target price on the stock. Morgan Stanley restated an equal weight rating and issued a $20.00 price objective on shares of Horizon Pharma PLC in a research report on Tuesday, February 28th. Piper Jaffray Companies lowered their price objective on Horizon Pharma PLC from $32.00 to $30.00 and set an overweight rating on the stock in a research report on Friday, March 24th. Finally, BMO Capital Markets restated a buy rating and issued a $24.00 price objective on shares of Horizon Pharma PLC in a research report on Wednesday, March 29th. Four equities research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company presently has a consensus rating of Buy and an average target price of $21.38.
Shares of Horizon Pharma PLC (HZNP) opened at 10.69 on Tuesday. Horizon Pharma PLC has a one year low of $9.45 and a one year high of $23.44. The stock’s market cap is $1.74 billion. The stock’s 50 day moving average is $12.66 and its 200-day moving average is $15.74.
Horizon Pharma PLC (NASDAQ:HZNP) last posted its quarterly earnings data on Monday, May 8th. The biopharmaceutical company reported $0.21 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.25 by $0.04. Horizon Pharma PLC had a negative net margin of 1.34% and a positive return on equity of 22.73%. The company had revenue of $220.90 million for the quarter, compared to analyst estimates of $248.71 million. During the same quarter last year, the company earned $0.34 EPS. The business’s revenue was up 7.9% compared to the same quarter last year. On average, equities analysts forecast that Horizon Pharma PLC will post $0.85 EPS for the current year.
ILLEGAL ACTIVITY NOTICE: This piece was originally reported by Community Financial News and is owned by of Community Financial News. If you are viewing this piece on another website, it was illegally stolen and republished in violation of United States and international copyright and trademark law. The legal version of this piece can be accessed at https://www.com-unik.info/2017/06/04/horizon-pharma-plc-hznp-rating-lowered-to-neutral-at-mizuho-updated-updated.html.
In related news, Director Michael G. Grey bought 10,000 shares of the business’s stock in a transaction on Wednesday, May 10th. The stock was acquired at an average cost of $9.48 per share, with a total value of $94,800.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 2.10% of the stock is owned by company insiders.
Several hedge funds have recently modified their holdings of HZNP. BlackRock Inc. increased its stake in shares of Horizon Pharma PLC by 68,479.5% in the first quarter. BlackRock Inc. now owns 13,261,212 shares of the biopharmaceutical company’s stock worth $196,001,000 after buying an additional 13,241,875 shares during the period. Consonance Capital Management LP bought a new stake in shares of Horizon Pharma PLC during the third quarter worth about $67,061,000. Deerfield Management Co. increased its stake in shares of Horizon Pharma PLC by 39.2% in the fourth quarter. Deerfield Management Co. now owns 8,956,988 shares of the biopharmaceutical company’s stock worth $144,924,000 after buying an additional 2,522,549 shares during the period. Norges Bank acquired a new position in Horizon Pharma PLC during the fourth quarter worth $31,467,000. Finally, Highbridge Capital Management LLC boosted its position in Horizon Pharma PLC by 128.2% in the first quarter. Highbridge Capital Management LLC now owns 1,545,169 shares of the biopharmaceutical company’s stock worth $22,837,000 after buying an additional 867,927 shares in the last quarter. 88.09% of the stock is owned by institutional investors and hedge funds.
Horizon Pharma PLC Company Profile
Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.
What are top analysts saying about Horizon Pharma PLC? – Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts’ recommendations for for Horizon Pharma PLC and related companies.